MedTrace Logo

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF

NCT02780180 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2018-10-16

No results posted yet for this study

Summary

Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.

A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF.

QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models.

This study investigates the safety and efficacy of QGC001 in HF patients.

Conditions

Interventions

DRUG

QGC001

DRUG

Placebo

Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg

Sponsors & Collaborators

  • Quantum Genomics SA

    lead INDUSTRY

Principal Investigators

  • Faiez Zannad, MD · Centre d'investigation clinique CHU-Nancy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • Czechia
  • France
  • Germany
  • Hungary
  • Netherlands
  • Norway
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780180 on ClinicalTrials.gov